Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
3,110 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | recruiting | Phase 1 / Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 17, 2026 | clinicaltrials |
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | recruiting | Phase 2 | 100 | Nurix Therapeutics, Inc.INDUSTRY | 5 |
| Sep 17, 2026 |
| clinicaltrials |
| NCT07407933 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 118 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 9 | Sep 17, 2026 | clinicaltrials |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation(AUGMENT-101) | recruiting | Phase 1 / Phase 2 | 447 | Syndax PharmaceuticalsINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT04077099 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Regeneron PharmaceuticalsINDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06268574 | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML(RIVER-52) | terminated | Phase 2 | 62 | Ryvu Therapeutics SAINDUSTRY | 4 | Sep 16, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 47 | GlaxoSmithKlineINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT07332455 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC | recruiting | Phase 1 / Phase 2 | 54 | GlaxoSmithKlineINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | recruiting | Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 13 | Sep 16, 2026 | clinicaltrials |
| NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum | recruiting | Phase 2 | 140 | Vividion Therapeutics, Inc.INDUSTRY | 22 | Sep 16, 2026 | clinicaltrials |
| NCT07823686 | Tracheal Replacement Using A Cryopreserved Aortic Allograft For R0 Resection In Locally Advanced Thyroid Cancer (TRITON 02 Tracheal Replacement In ThyrOid caNcer)(TRITON 02) | not yet recruiting | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | active not recruiting | Phase 2 | 340 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 15, 2026 | clinicaltrials |
| NCT03818386 | Radiotherapy of Multiple Brain Metastases Using AGuIX®(NANORAD2) | completed | Phase 2 | 106 | University Hospital, GrenobleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | recruiting | Phase 2 | 140 | Cogent Biosciences, Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT05410145 | A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 442 | D3 Bio (Wuxi) Co., LtdINDUSTRY | 10 | Sep 15, 2026 | clinicaltrials |
| NCT05529251 | De-escalation Study for Stage IIa/IIb < 3 cm Seminoma(EDEN) | recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 62 | Hoffmann-La RocheINDUSTRY | 6 | Sep 15, 2026 | clinicaltrials |
| NCT06668493 | Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis(LUNAR) | recruiting | Phase 1 / Phase 2 | 20 | Ferring PharmaceuticalsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT06782373 | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | active not recruiting | Phase 2 | 156 | Swedish Orphan BiovitrumINDUSTRY | 8 | Sep 15, 2026 | clinicaltrials |
| NCT07802652 | Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma(IMMUSARC-7012) | not yet recruiting | Phase 2 | 80 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00467506 | Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma(RIT in MTC) | completed | Phase 2 | — | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00841724 | Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies(ITT 08-01) | completed | Phase 2 | 82 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00863148 | Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)(Cloric) | completed | Phase 2 | 30 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01188174 | Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure(setric) | completed | Phase 2 | 26 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01219816 | Multi-centric Study(CHEPRALL) | completed | Phase 2 | 57 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01279694 | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)(CARMYSAP) | completed | Phase 1 / Phase 2 | 72 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01300143 | Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma(TACERTE) | completed | Phase 2 | 126 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01541280 | VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome(VIDAZA-DLI) | completed | Phase 2 | 30 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01572181 | Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens(FB4-PEDIA) | completed | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01936532 | Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)(IFM2013-06) | completed | Phase 2 | 42 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 107 | Acerta Pharma BVINDUSTRY | 7 | Sep 14, 2026 | clinicaltrials |
| NCT02558816 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients(OAsIs) | completed | Phase 1 / Phase 2 | 48 | Nantes University HospitalOTHER | 2 | Sep 14, 2026 | clinicaltrials |
| NCT02587247 | ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer(iTEP Colon) | completed | Phase 2 | 11 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT04246086 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 237 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04771130 | A Study of BGB-11417 in Participants With Myeloid Malignancies | recruiting | Phase 1 / Phase 2 | 260 | BeOne MedicinesINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 460 | Bristol-Myers SquibbINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | completed | Phase 2 | 63 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 14, 2026 | clinicaltrials |
| NCT06638502 | Safety of HRX215 in Patients After Minor and Major Liver Resection | recruiting | Phase 1 / Phase 2 | 80 | HepaRegeniX GmbHINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT07243470 | Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors(TARLATEM) | recruiting | Phase 1 / Phase 2 | 70 | Centre Leon BerardOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)(ZEN-CLL) | not yet recruiting | Phase 2 | 95 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 14 days agoSource updated unknownsource: clinicaltrials